Navigation Links
Current and Emerging Therapies Have No Advantage Over Pfizer's Lyrica in Their Effect on Patients' Quality of Life in the Treatment of Diabetic Neuropathy
Date:3/13/2008

However, Owing to Safety and Delivery End Points, Drugs from Eli Lilly and Boehringer Ingelheim Will Remain as the Gold Standard Treatments, According

to a New Report from Decision Resources

WALTHAM, Mass., March 13 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms focusing on pharmaceutical and healthcare issues, finds that a drug's effect on a patient's quality of life is the attribute that most influences neurologists' prescribing decisions in the treatment of diabetic neuropathy. Clinical data and expert opinion show that current and emerging therapies have no advantage in this attribute over Pfizer's Lyrica.

The new report entitled Diabetic Neuropathy: Moderate Pain Relief No Longer Enough-Physicians Expect More-Effective Therapies finds that if an agent offering pain relief superior to that of sales-leading Lyrica were to be launched, it would earn a 33% patient share, according to surveyed neurologists. The report also finds that, although Lyrica is the sales leader in the diabetic neuropathy drug market, the current and future gold standard treatment for the indication is Eli Lilly's Cymbalta/Boehringer Ingelheim's Xeristar.

Although the efficacy of Cymbalta/Xeristar is equal to that of Lyrica, Cymbalta/Xeristar outscores Lyrica in safety and delivery end points. In particular, Cymbalta/Xeristar does not cause weight gain and is associated with less symptoms of dizziness than Lyrica.

"Based on available data and expert opinion, we do not expect any therapy under development to displace Cymbalta/Xeristar as the clinical gold standard for diabetic neuropathy," said Marcus Bain, Ph.D., analyst at Decision Resources. "Although some therapies in development hold promise, most of them earned inferior scores in efficacy, safety and tolerability, and/or delivery features when compared with Cymbalta/Xeristar."

About the Report

Diabetic Neuropathy: Moderate Pain
'/>"/>

SOURCE Decision Resources
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related medicine news :

1. Arrow International Urges Shareholders To Vote for Approval of the $45.50 Teleflex Inc. Merger and for the Current Board of Directors
2. Glass Lewis Recommends Arrow Shareholders Vote on the White Proxy Card for Merger With Teleflex and for Current Board of Directors at Arrow Annual Meeting
3. Arrow International Sends Letter Reminding Shareholders to Vote White Proxy Card in Support of Teleflex Merger and Election of Current Board of Directors
4. Morris Animal Foundation 2008 Sponsorship Guide Available, Details Current Animal Health Studies
5. Experimental drug boosts survival in recurrent ovarian cancer
6. Office of Administration Announces Plan to Preserve Health Care Benefits for Current, Future Retired Commonwealth Employees
7. Stop eating for two: obese moms-to-be should gain less weight than currently recommended
8. Switching to MA Coverage Unlikely for Current Beneficiaries With MediGap or Medicare Only
9. The Current Recall of Boy Scouts of Americas Plastic Badges Does Not Affect Embroidered Insignia, Badges & Awards Produced by Lion Brothers Company Inc.
10. Purified Fish Oil Concentrates Offer Solution to Current Seafood Controversy for Pregnant and Breastfeeding Women!
11. ALEVE-D(R) Sinus & Cold Offers Option for the More Than 50% of Consumers Not Satisfied with Current Sinus Medication
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/2/2015)... ... ... Molecular biologists in New South Wales say a protein linked to cell ... an article on the new research. Click here to read it now. ... tissue samples from 42 patients with peritoneal mesothelioma and found a direct correlation with ...
(Date:8/1/2015)... ... 2015 , ... Western University of Health Sciences’ newest class ... growing percentage of U.S. physicians, and reflects the diversity of the communities where ... message delivered by John W. Becher, DO, president of the American Osteopathic Association, ...
(Date:8/1/2015)... ... August 01, 2015 , ... Calvary Hospital today announced that it is embarking ... The goal is to bring this Torah – dating from 1880 – back to ... religious services. , Scroll No. 515, from the town of Taus-Domazlice, is on ...
(Date:8/1/2015)... CT (PRWEB) , ... August 01, 2015 , ... ... Point Partners I, L.P. (“GPP”) portfolio company has acquired Premier Physical Therapy & ... it into its portfolio of state-of-the-art clinics. , “Our acquisition of Premier Physical ...
(Date:8/1/2015)... ... ... BeverlyD, owner and founder of BeverlyD Luxe Organic Hair Care, has announced her ... to kick off the campaign for healing and Well-Being. , BeverlyD has helped women ... of raw, organic hair care products, as well as her book, Hair Now!— The ...
Breaking Medicine News(10 mins):Health News:Scientists Link Protein Marker with Mesothelioma Prognosis in New Study, According to Surviving Mesothelioma 2Health News:COMP-Northwest Welcomes Class of 2019 2Health News:COMP-Northwest Welcomes Class of 2019 3Health News:COMP-Northwest Welcomes Class of 2019 4Health News:COMP-Northwest Welcomes Class of 2019 5Health News:Calvary Hospital Announces Plans to Restore Historic Torah 2Health News:Calvary Hospital Announces Plans to Restore Historic Torah 3Health News:Professional Physical Therapy Now Largest Outpatient Physical Therapy Provider in Northeast With Acquisition of Premier Physical Therapy & Wellness 2Health News:March4thforWellBeing Foundation Kickoff 2
... DEERFIELD, Ill., Oct. 15 Baxter International,(NYSE: BAX ... third,quarter 2007 financial results on Thursday, October 18, 2007, ... access the call, please dial,866-793-1307 (domestic) or 703-639-1309 (international). ... to the start of the call for the,operator to ...
... 20 Years of Public Company Experience, MOUNTAIN VIEW, Calif., ... the appointment of James B.,Hawkins, president and CEO of Natus ... "We are excited that Jim Hawkins has decided to ... chairman of the board at,IRIDEX. "Jim brings to our Board ...
... BOSTON, Oct. 15 It could be one of ... if they,re,turning away from their family in favor of their ... A study led by Simmons School of Social Work ... adolescents that they feel,valued by their family, and is an ...
... patient health, WASHINGTON, Oct. 15 The move ... patients to spend their own,money on medical care is ... their own lives. That is the conclusion of Kent ... to Spend Your Own,Money on Medical Care: A Common ...
... Transitioning to Independence, SAN FRANCISCO, Oct. ... relationship with national human resources,outsourcing company TriNet ... investment advisors and their employees. As part ... who custody,assets with Schwab will now be ...
... Cryo-Cell,International, Inc. (OTC Bulletin Board: CCEL) (the "Company"), ... cord blood banks, today,announced results for the third ... for the third quarter were approximately $4.6,million, remaining ... third quarter of 2006. The Company reported a ...
Cached Medicine News:Health News:James B. Hawkins Appointed to IRIDEX Board of Directors 2Health News:James B. Hawkins Appointed to IRIDEX Board of Directors 3Health News:A Best-Kept Secret of Your Teen: They Really Do Care What You Think, Simmons College Study Shows 2Health News:How to Beat the High Cost of Living 2Health News:Schwab Institutional Introduces Healthcare and Benefits Assistance for Independent Advisor Firms 2Health News:Schwab Institutional Introduces Healthcare and Benefits Assistance for Independent Advisor Firms 3Health News:Schwab Institutional Introduces Healthcare and Benefits Assistance for Independent Advisor Firms 4Health News:Cryo-Cell International, Inc. Reports Third Quarter 2007 Results 2Health News:Cryo-Cell International, Inc. Reports Third Quarter 2007 Results 3Health News:Cryo-Cell International, Inc. Reports Third Quarter 2007 Results 4Health News:Cryo-Cell International, Inc. Reports Third Quarter 2007 Results 5
(Date:7/30/2015)... DIEGO, July 30, 2015  ResMed Inc. (NYSE: ... June 30, 2015.  Revenue for the quarter was $453.1 ... ended June 30, 2014 (a 17 percent increase on ... consistent with the quarter ended June 30, 2014.  Diluted ... with the quarter ended June 30, 2014.  ...
(Date:7/30/2015)... Calif. , July 30, 2015  EP ... /Alcon executives have recently contacted the Company about ... begin as early as Monday, August 3, 2015.  ... quoted as saying that the coming electronic contact ... of dollars over the next several years.  Novartis ...
(Date:7/30/2015)... , July 30, 2015  Unichem Pharmaceuticals ( ... one lot of Hydrochlorothiazide tablets 25 mg 1000-count bottle ... as a precautionary measure due to the identification of ... product. The risk associated with mistakenly ... is the increased probability of experiencing Clopidogrel,s side effects ...
Breaking Medicine Technology:ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 2ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 3ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 4ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 5ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 6ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 7ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 8ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 9ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 10ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 11ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 12ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 13ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 14ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 15ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 16Unichem Pharmaceuticals (USA), Inc. Issues a Voluntary Nationwide Recall of Hydrochlorothiazide Tablets Due to the Potential Presence of Foreign Tablets 2
Cementless hip stem revisions offering optimal version setting for each patient. Compatible with modular link ceramic or cobalt chromium femoral heads with up to 4 neck lengths, or the link saddle de...
The proximally modular S-ROM Total Hip System provides custom capability at non-custom prices and is competitive with conventional porous coated systems....
Exactech's AcuMatch C-Series (Cemented Femoral Stem) is designed to provide solutions to the problems which compromise both the short and long term successful outcome of cemented hip arthroplasty....
Severe revision options for the knee and hip...
Medicine Products: